• Rakovina Therapeutics secured an exclusive, worldwide, perpetual license to Artemis Therapeutics' Artemis.AI platform for DNA-damage response oncology drug discovery and development.
• Consideration totals C$1 million in common shares issued in two tranches, with no cash license fees.
• The licensee owns compounds and data generated using the platform, with no royalties or milestone payments unless separately agreed for co-development.
• Artemis has a 60-day option to co-develop designated platform-derived compounds, sharing costs, risks and upside proportionately to contributions.
• The agreement took effect November 9, 2026; exclusivity may lapse following prolonged inactivity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rakovina Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100900PRIMZONEFULLFEED9874347) on November 10, 2026, and is solely responsible for the information contained therein.